title: Comparative study of liposomes, transfersomes and ethosomes as carriers for improving topical delivery of celecoxib.
abstract: Topical administration of celecoxib proved to be an effective mean of preventing skin cancer development and improving anticancer drugs effectiveness in skin tumors treatment. The aim of this study was the development of an effective topical formulation of celecoxib, able to promote drug skin delivery, providing its in depth penetration through the skin layers. Three kinds of vesicular formulations have been investigated as drug carriers: liposomes containing a surfactant, or transfersomes and ethosomes, containing suitable edge activators. Firstly, the effect of membrane composition variations on the system performance has been evaluated for each vesicle type. Selected formulations were characterized for particle size, polydispersity index and encapsulation efficiency. The best formulations were subjected to ex vivo permeation studies through excised human skin. All vesicular formulations markedly (p < 0.001) improved the drug amount penetrated into the skin with respect to an aqueous suspension, from 2.0 to 6.5, up to 9.0 folds for liposomes, transfersomes and ethosomes, respectively. In particular, ethosomes containing Tween 20 as edge activator not only showed the best vesicle dimensions and homogeneity, and the highest encapsulation efficacy (54.4%), but also enabled the highest increase in drug penetration through the skin, probably due to the simultaneous presence in their composition of ethanol and Tween 20, both acting as permeation enhancers. Therefore, among the various vesicular formulations examined in the study, Tween 20-ethosomes can be considered the most promising one as carrier for topical celecoxib applications aimed to prevent skin cancer development and increase the anticancer drugs effectiveness against skin tumors.
authors.affiliation: Department of Pharmaceutical Sciences, Faculty of Pharmacy, University of Florence, Florence, Italy.
authors.forename: Marco
authors.initials: M
authors.lastname: Bragagni
authors.forename: Natascia
authors.initials: N
authors.lastname: Mennini
authors.forename: Francesca
authors.initials: F
authors.lastname: Maestrelli
authors.forename: Marzia
authors.initials: M
authors.lastname: Cirri
authors.forename: Paola
authors.initials: P
authors.lastname: Mura
mesh_terms: D000279:Administration, Cutaneous; D000068579:Celecoxib; D002626:Chemistry, Pharmaceutical; D004337:Drug Carriers; D006801:Humans; D008081:Liposomes; D010316:Particle Size; D011720:Pyrazoles / Q000008:administration & dosage* / Q000737:chemistry / Q000493:pharmacokinetics; D012867:Skin / Q000378:metabolism*; D013449:Sulfonamides / Q000008:administration & dosage* / Q000737:chemistry / Q000493:pharmacokinetics
chemical_list: D004337:Drug Carriers; D008081:Liposomes; D011720:Pyrazoles; D013449:Sulfonamides; D000068579:Celecoxib